Baseline characteristics of patients with RA entering randomised trial
| Placebo n=7 | Infliximab n=11 | p Value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 55.86 (15.89) | 61.30 (11.05) | 0.42 |
| Gender (proportion female) | 4/7 | 8/11 | 0.31 (χ2 test) |
| Cardiovascular risk | |||
| BMI (kg/m2) | 25.88 (0.55) | 24.98 (5.11) | 0.73 |
| Total cholesterol (mmol/L) | 5.05(1.42) | 5.01 (1.5) | 0.96 |
| HDL-c (mmol/L) | 1.10 (0.22) | 0.97 (0.17) | 0.20 |
| LDL-c (mmol/L) | 3.20 (0.95) | 2.90 (1.34) | 0.62 |
| Triglyceride (mmol/L) | 1.67 (1.00) | 2.52 (0.81) | 0.63 |
| Glucose (mg/dL) | 4.60 (0.70) | 4.75 (1.24) | 0.59 |
| Systolic BP (mm Hg) | 140.70 (7.27) | 132.5 (4.67) | 0.33 |
| Diastolic BP (mm Hg) | 75.71 (3.96) | 76.00 (3.70) | 0.96 |
| HDL function | |||
| Nitric oxide bioavailability (% buffer-treated cells) | 81.81 (3.97) | 84.23 (6.23) | 0.37 |
| Superoxide production (nmol/O2-/100 000 cells) | 4.37 (1.71) | 3.90 (1.66) | 0.56 |
| Paraoxonase-1 activity (μmol p-nitrophenol/L/serum/min) | 137.52 (1.71) | 148.24 (14.49) | 0.09 |
| Efflux capacity (%) | 12.25 (2.04) | 13.52 (1.26) | 0.31 |
| RA disease activity | |||
| CRP (mg/L) | 37.65 [19.48–64.31] | 26.83 [14.37–37.33] | 0.22 |
| ESR (mm/hours) | 30.00 [22.00–76.00] | 25.00 [14.00–50.50] | 0.36 |
| DAS28—CRP score | 6.08 (0.71) | 5.17 (1.13) | 0.09 |
| DAS28—ESR score | 5.59 (0.85) | 4.68 (1.56) | 0.15 |
Values expressed as mean (SD) and median [IQR] for non-normally distributed data. Comparisons between groups were performed using the independent t-test. Categorical variables were compared using Fisher's exact χ2 test. Comparisons for non-parametric measurements were performed using Mann-Whitney test.
APO4, Apolipoprotein A; BMI, body mass index; BP, blood pressure; CRP, C reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; RA, rheumatoid arthritis.